Cargando…
QSAR, Molecular Docking, MD Simulation and MMGBSA Calculations Approaches to Recognize Concealed Pharmacophoric Features Requisite for the Optimization of ALK Tyrosine Kinase Inhibitors as Anticancer Leads
ALK tyrosine kinase ALK TK is an important target in the development of anticancer drugs. In the present work, we have performed a QSAR analysis on a dataset of 224 molecules in order to quickly predict anticancer activity on query compounds. Double cross validation assigns an upward plunge to the g...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9370430/ https://www.ncbi.nlm.nih.gov/pubmed/35956900 http://dx.doi.org/10.3390/molecules27154951 |
_version_ | 1784766794891788288 |
---|---|
author | Jawarkar, Rahul D. Sharma, Praveen Jain, Neetesh Gandhi, Ajaykumar Mukerjee, Nobendu Al-Mutairi, Aamal A. Zaki, Magdi E. A. Al-Hussain, Sami A. Samad, Abdul Masand, Vijay H. Ghosh, Arabinda Bakal, Ravindra L. |
author_facet | Jawarkar, Rahul D. Sharma, Praveen Jain, Neetesh Gandhi, Ajaykumar Mukerjee, Nobendu Al-Mutairi, Aamal A. Zaki, Magdi E. A. Al-Hussain, Sami A. Samad, Abdul Masand, Vijay H. Ghosh, Arabinda Bakal, Ravindra L. |
author_sort | Jawarkar, Rahul D. |
collection | PubMed |
description | ALK tyrosine kinase ALK TK is an important target in the development of anticancer drugs. In the present work, we have performed a QSAR analysis on a dataset of 224 molecules in order to quickly predict anticancer activity on query compounds. Double cross validation assigns an upward plunge to the genetic algorithm–multi linear regression (GA-MLR) based on robust univariate and multivariate QSAR models with high statistical performance reflected in various parameters like, fitting parameters; R(2) = 0.69–0.87, F = 403.46–292.11, etc., internal validation parameters; Q(2)(LOO) = 0.69–0.86, Q(2)(LMO) = 0.69–0.86, CCC(cv) = 0.82–0.93, etc., or external validation parameters Q(2)(F1) = 0.64–0.82, Q(2)(F2) = 0.63–0.82, Q(2)(F3) = 0.65–0.81, R(2)(ext) = 0.65–0.83 including RMSE(tr) < RMSE(cv). The present QSAR evaluation successfully identified certain distinct structural features responsible for ALK TK inhibitory potency, such as planar Nitrogen within four bonds from the Nitrogen atom, Fluorine atom within five bonds beside the non-ring Oxygen atom, lipophilic atoms within two bonds from the ring Carbon atoms. Molecular docking, MD simulation, and MMGBSA computation results are in consensus with and complementary to the QSAR evaluations. As a result, the current study assists medicinal chemists in prioritizing compounds for experimental detection of anticancer activity, as well as their optimization towards more potent ALK tyrosine kinase inhibitor. |
format | Online Article Text |
id | pubmed-9370430 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93704302022-08-12 QSAR, Molecular Docking, MD Simulation and MMGBSA Calculations Approaches to Recognize Concealed Pharmacophoric Features Requisite for the Optimization of ALK Tyrosine Kinase Inhibitors as Anticancer Leads Jawarkar, Rahul D. Sharma, Praveen Jain, Neetesh Gandhi, Ajaykumar Mukerjee, Nobendu Al-Mutairi, Aamal A. Zaki, Magdi E. A. Al-Hussain, Sami A. Samad, Abdul Masand, Vijay H. Ghosh, Arabinda Bakal, Ravindra L. Molecules Article ALK tyrosine kinase ALK TK is an important target in the development of anticancer drugs. In the present work, we have performed a QSAR analysis on a dataset of 224 molecules in order to quickly predict anticancer activity on query compounds. Double cross validation assigns an upward plunge to the genetic algorithm–multi linear regression (GA-MLR) based on robust univariate and multivariate QSAR models with high statistical performance reflected in various parameters like, fitting parameters; R(2) = 0.69–0.87, F = 403.46–292.11, etc., internal validation parameters; Q(2)(LOO) = 0.69–0.86, Q(2)(LMO) = 0.69–0.86, CCC(cv) = 0.82–0.93, etc., or external validation parameters Q(2)(F1) = 0.64–0.82, Q(2)(F2) = 0.63–0.82, Q(2)(F3) = 0.65–0.81, R(2)(ext) = 0.65–0.83 including RMSE(tr) < RMSE(cv). The present QSAR evaluation successfully identified certain distinct structural features responsible for ALK TK inhibitory potency, such as planar Nitrogen within four bonds from the Nitrogen atom, Fluorine atom within five bonds beside the non-ring Oxygen atom, lipophilic atoms within two bonds from the ring Carbon atoms. Molecular docking, MD simulation, and MMGBSA computation results are in consensus with and complementary to the QSAR evaluations. As a result, the current study assists medicinal chemists in prioritizing compounds for experimental detection of anticancer activity, as well as their optimization towards more potent ALK tyrosine kinase inhibitor. MDPI 2022-08-03 /pmc/articles/PMC9370430/ /pubmed/35956900 http://dx.doi.org/10.3390/molecules27154951 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jawarkar, Rahul D. Sharma, Praveen Jain, Neetesh Gandhi, Ajaykumar Mukerjee, Nobendu Al-Mutairi, Aamal A. Zaki, Magdi E. A. Al-Hussain, Sami A. Samad, Abdul Masand, Vijay H. Ghosh, Arabinda Bakal, Ravindra L. QSAR, Molecular Docking, MD Simulation and MMGBSA Calculations Approaches to Recognize Concealed Pharmacophoric Features Requisite for the Optimization of ALK Tyrosine Kinase Inhibitors as Anticancer Leads |
title | QSAR, Molecular Docking, MD Simulation and MMGBSA Calculations Approaches to Recognize Concealed Pharmacophoric Features Requisite for the Optimization of ALK Tyrosine Kinase Inhibitors as Anticancer Leads |
title_full | QSAR, Molecular Docking, MD Simulation and MMGBSA Calculations Approaches to Recognize Concealed Pharmacophoric Features Requisite for the Optimization of ALK Tyrosine Kinase Inhibitors as Anticancer Leads |
title_fullStr | QSAR, Molecular Docking, MD Simulation and MMGBSA Calculations Approaches to Recognize Concealed Pharmacophoric Features Requisite for the Optimization of ALK Tyrosine Kinase Inhibitors as Anticancer Leads |
title_full_unstemmed | QSAR, Molecular Docking, MD Simulation and MMGBSA Calculations Approaches to Recognize Concealed Pharmacophoric Features Requisite for the Optimization of ALK Tyrosine Kinase Inhibitors as Anticancer Leads |
title_short | QSAR, Molecular Docking, MD Simulation and MMGBSA Calculations Approaches to Recognize Concealed Pharmacophoric Features Requisite for the Optimization of ALK Tyrosine Kinase Inhibitors as Anticancer Leads |
title_sort | qsar, molecular docking, md simulation and mmgbsa calculations approaches to recognize concealed pharmacophoric features requisite for the optimization of alk tyrosine kinase inhibitors as anticancer leads |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9370430/ https://www.ncbi.nlm.nih.gov/pubmed/35956900 http://dx.doi.org/10.3390/molecules27154951 |
work_keys_str_mv | AT jawarkarrahuld qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads AT sharmapraveen qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads AT jainneetesh qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads AT gandhiajaykumar qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads AT mukerjeenobendu qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads AT almutairiaamala qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads AT zakimagdiea qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads AT alhussainsamia qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads AT samadabdul qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads AT masandvijayh qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads AT ghosharabinda qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads AT bakalravindral qsarmoleculardockingmdsimulationandmmgbsacalculationsapproachestorecognizeconcealedpharmacophoricfeaturesrequisitefortheoptimizationofalktyrosinekinaseinhibitorsasanticancerleads |